Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DW2012 is a probiotic functional material candidate, specifically a strain of *Lactobacillus fermentum*, developed by Dongwha Pharmaceutical to improve sleep quality. Categorized within the company's 'Functional Materials' pipeline, it is intended for use as a health functional food (HFF) rather than a prescription pharmaceutical. DW2012 is designed to enhance sleep health, potentially through the modulation of the gut-brain axis and the regulation of neurotransmitters associated with the sleep-wake cycle. As of recent reports, the strain is undergoing human application trials in South Korea to evaluate its efficacy in improving sleep duration and efficiency, targeting the growing consumer demand for natural, non-pharmacological sleep aids.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on DW2012.